The effect of ubiquitination and deubiquitination to imatinib resistance in gastrointestinal stromal tumors
{{output}}
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor. Imatinib, as a receptor-type tyrosine kinase inhibitor (TKI), becomes a first-line drug for adjuvant therapy and prognosis. However, patients are facing with the problem of primary and... ...
